Bharat Biotech’s Covaxin shows interim clinical efficacy of 81%
Bharat Biotech’s Covaxin demonstrated an 81% efficacy in preventing Covid-19 after the second dose. The numbers are as per the interim results of Phase III trials made public by its developer Bharat Biotech. The first interim analysis is based on 43 cases of Covid-19. Bharat Biotech expects to share further details of the trial results as additional data becomes available.